ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer

Cedó, Lídia; García-León, Annabel; Baila-Rueda, Lucía; Santos, David; Grijalva, Víctor; Martínez-Cignoni, Melanie Raquel; Carbó, José M.; Metso, Jari; López‐Vilaró, Laura; Zorzano, António; Valledor, Annabel F.; Cenarro, Ana; Jauhiainen, Matti; Lerma, Enrique; Fogelman, Alan M.; Reddy, Srinivasa T.; Escolà‐Gil, Joan Carles; Blanco‐Vaca, Francisco

doi:10.1038/srep36387

Cited by 33 publications

(36 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the process of tumor occurrence and development, apoA-I has been reported to significantly inhibit the growth and invasion of tumor cells [60]. In addition, several studies have found that in multiple xenograft mice models, HDL that contains human apoA-I effectively inhibits the activities induced by tumors in ovarian carcinoma, malignant melanoma, and Lewis lung cancer [61,62]. When focusing on the proliferation of BC cells, these studies assessed the polymorphisms of apoA-I that are associated with BC in great detail and even discussed its effect on metastasis of this tumor.…”

Section: Apoa-i Apoj and Bcmentioning

confidence: 99%

“…However, the overexpression of apoA-I in serum may not absolutely benefit BC patients. First, redundant apoA-I increases 27-hydroxycholesterol (27-HC) expression, which generally advances breast tumor growth [62]. Second, the reduction in oxidized LDL caused by the overexpression of apoA-I equal to the increase in the LDL level promotes multiplication and migration in ER-negative BC cells, and oxidized LDL may promote MCF-7 cell proliferation [66,67].…”

Section: Apoa-i Apoj and Bcmentioning

confidence: 99%

“…Interestingly, Lídia et al confirmed the role of apoA-I in mammary tissues through a mouse model with inherited BC. After administrating one specific apoA-I mimetic peptide (D-4F) in the BC mouse model, they found that although D-4F does not decrease 27-HC expression in breast tissue, it inhibits oxidized LDL levels in plasma and prevents the proliferation of BC MCF-7 cells [62]. Overall, these articles provided sufficient information about apoA-I and BC from the occurrence to distant metastasis and explored the effects of apoA-I expression in serum and mammary tissues for BC.…”

Section: Apoa-i Apoj and Bcmentioning

confidence: 99%

See 2 more Smart Citations

Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer

Zhou

Luo

2020

Clin Transl Oncol

View full text Add to dashboard Cite

Apolipoproteins, the key components of lipoproteins, play vital roles in the combination and transportation of lipids. Numerous research articles have accumulated solid evidence that lipoproteins are closely related to various types of tumorigenesis. In this review, we focused on the associations between several apolipoproteins and breast carcinoma and distinguished the effects and significance of apolipoproteins in different locations to validate their roles in breast carcinoma development. For example, apoD and apoE in serum are viewed as risk factors for breast carcinoma. ApoD, apoE and apoA-I in mammary tissues inhibit tumor growth. Moreover, apoB, apoJ and apoA-I have the potential to function as diagnostic or prognostic markers in the clinic. ApoEdp and apoJ treatment on breast carcinoma could significantly restrict tumor growth. In general, the aim of this review was to further analyze the associations between some members of the apolipoprotein family and breast cancer.

show abstract

Section: Apoa-i Apoj and Bcmentioning

confidence: 99%

Section: Apoa-i Apoj and Bcmentioning

confidence: 99%

Section: Apoa-i Apoj and Bcmentioning

confidence: 99%

See 1 more Smart Citation

Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer

Zhou

Luo

2020

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

“…One study demonstrated that the absence of ABCG1 inhibited tumor growth through phenotypic shift of the macrophages from a tumor-promoting M2 to a tumor-fighting M1 within the tumor [30]. In the mouse model of ovarian cancer and breast cancer model, Apo A1 mimetic peptide significantly inhibited the development of tumors [31,32]. However, no study of relation between Apo A1 and multiple myeloma was done.…”

Section: Discussionmentioning

confidence: 99%

Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma

Liang¹,

Li²,

Fu³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

This study is to explore the prognostic significance of serum lipid profiles in patients with multiple myeloma (MM). The study retrospectively enrolled 307 MM patients in Zhongshan Hospital, Shanghai, China, from 2007 to 2016. We evaluated the prognostic significance of the pre-diagnostic serum lipid profile [cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein (HDL), Apolipoprotein A1 (Apo A1) and Apolipoprotein B (Apo B)]. Prognostic factors identified through univariate and multivariate analysis were used to construct a new model based on Lasso Cox regression. Results indicated that lipid levels showed significant difference between ISS stages: Apo A1, Apo B, Cholesterol and LDL levels were lower in late ISS stage. However, only Apo A1 showed statistically significance in overall survival (OS), progression free survival (PFS) and cause specific survival (CSS) (P=0.038, P=0.028, P=0.011) in univariate Cox regression. Patients with higher Apo A1 displayed longer OS (median OS, 67 months vs. 30 months; P<0.001). Also, Apo A1 was revealed to be an independent prognostic indicator through multivariate analysis. Combining the Apo A1 level, Zhongshan Score model was constructed with Lasso regression for prognosis prediction. This model exhibited higher accuracy than International Staging System (ISS) and Durie and Salmon (DS) system. In conclusion, among all the serum lipid profiles, serum Apo A1 is a powerful prognostic indicator for patients with MM.

show abstract

“…This experiment showed that ApoA-I could increase the expression of CD 8T cells, M1 anti-tumor macrophages, reduce angiogenesis, reduce tumor invasion and metastasis.Other researchers also found that ApoA-I controls the rate of cell proliferation in a tumor and the tumor growth. Pro-in ammatory and pro-angiogenic lysophospholipids such as lysophosphatidic acid (LPA) have been shown to be associated with tumor progression and poor prognosis, and are normally cleared from the serum by Apo A1 [12][13].…”

Section: Disscussionmentioning

confidence: 99%

Decreased Apolipoprotein A-I Level Indicates Poor Prognosis in Hodgkin Lymphoma

Shen

Yang

Yang³

2020

Preprint

View full text Add to dashboard Cite

Background Recent studies have reported of an association between Abnormal lipid metabolism and many kind of malignant tumors, and the level of lipid varies with the outcome of the disease. Some data have indicated that the serum level of Apolipoprotein A-I(Apo A-I) in serum was down-regulated in some tumors, but there is few report about it in hodgkin lymphoma. In this study, we aimed to determine the change and clinical significance of serum level Apolipoprotein A-I in hodgkin lymphoma patients. Methods A total of 88 newly diagnosed cases of HL were analyzed retrospectively. Results Our study showed that the serum level of ApoA-I has significant differences in some clinical features of HL, and it dynamically changed with different stages. Divied patients by whether remission or not, we noticed that the non-remission group had lower ApoA-I than remission group. According the result of multivariate analysis decreased ApoA-I reduction become the independent risk factors of HL. On the basis of Kaplan-Meier survival analysis between high ApoA-I subgroup and low ApoA-I subgroup . we found the lower ApoA-I patients had short OS rate and PFS. The serum ApoA-I level was able to differentiate cases with poor outcomes from cases with good outcomes.Conclusions Our results showed that the serum level of ApoA-I was helpful for predicting HL prognosis.

show abstract

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer

Cited by 33 publications

References 52 publications

Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer

Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer

Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma

Decreased Apolipoprotein A-I Level Indicates Poor Prognosis in Hodgkin Lymphoma

Contact Info

Product

Resources

About